Progression of Platelet Counts in Treatment Naïve HIV/HCV Co-Infection
Copyright © 2013 SciRes. WJA
40
[8] A. Sarpatwari, et al., “Thromboembolic Events among
Adult Patients with Primary Immune Thrombocytopenia
in the United Kingdom General Practice Research Data-
base,” Haematologica, Vol. 95, No. 7, 2010, pp. 1167-
1175. doi:10.3324/haematol.2009.018390
[9] E. Y. Chiao, et al., “Risk of Immune Thrombocytopenic
Purpura and Autoimmune Hemolytic Anemia among 120
908 US Veterans with Hepatitis C Virus Infection,” For-
merly Archives of Internal Medicine, Vol. 169, No. 4,
2009, pp. 357-363. doi:10.1001/archinternmed.2008.576
[10] S. Panzer and E. Seel, “Is There an Increased Frequency
of Autoimmune Thrombocytopenia in Hepatitis C Infec-
tion? A Review,” Wiener Medizinische Wochenschrift,
Vol. 153, No. 19-20, 2003, pp. 417-420.
doi:10.1007/s10354-003-0028-x
[11] S. K. Rajan, B. M. Espina and H. A. Liebman, “Hepatitis
C Virus-Related Thrombocytopenia: Clinical and Labo-
ratory Characteristics Compared with Chronic Immune
Thrombocytopenic Purpura,” British Journal of Haema-
tology, Vol. 129, No. 6, 2005, pp. 818-824.
doi:10.1111/j.1365-2141.2005.05542.x
[12] P. S. Sullivan, et al., “Surveillance for Thrombocytopenia
in Persons Infected with HIV: Results from the Multistate
Adult and Adolescent Spectrum of Disease Project,”
Journal of Acquired Immune Deficiency Syndromes and
Human Retrovirology, Vol. 14, No. 4, 1997, pp. 374-379.
doi:10.1097/00042560-199704010-00011
[13] A. Scaradavou, “HIV-Related Thrombocytopenia,” Blood
Reviews, Vol. 16, No. 1, 2002, pp. 73-76.
doi:10.1054/blre.2001.0188
[14] L. Li, D.-K. Han and J. Lu, “Interferon-Alpha Induced
Severe Thrombocytopenia: A Case Report and Review of
the Literature,” World Journal of Gastroenterology, Vol.
16, No. 11, 2010, pp. 1414-1417.
doi:10.3748/wjg.v16.i11.1414
[15] N. Afdhal, et al., “Thrombocytopenia Associated with
Chronic Liver Disease,” Journal of Hepatology, Vol. 48,
No. 6, 2008, pp. 1000-1007.
doi:10.1016/j.jhep.2008.03.009
[16] M. M. Kitahata, et al., “Cohort Profile: The Centers for
AIDS Research Network of Integrated Clinical Systems,”
International Journal of Epidemiology, Vol. 37, No. 5,
2008, pp. 948-955. doi:10.1093/ije/dym231
[17] N. I. H. This, “National Institutes of Health Consensus
Development Conference Statement: Management of
Hepatitis C: 2002—June 10-12, 2002,” Hepatology, Vol.
36, No. 5B, 2002, pp. s3-s20.
doi:10.1053/jhep.2002.37117
[18] AIDSinfo, “Guidelines for the Use of Antiretroviral
Agents in HIV-1-Infected Adults and Adolescents,” 2011.
http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultanda
dolescentgl.pdf.
[19] P. Hui, et al., “The Frequency and Clinical Significance
of Thrombocytopenia Complicating Critical Illness: A
Systematic Review,” Chest, Vol. 139, No. 2, 2011, pp.
271-278. doi:10.1378/chest.10-2243
[20] K. S. Louie, et al., “Prevalence of Thrombocytopenia
among Patients with Chronic Hepatitis C: A Systematic
Review,” Journal of Viral Hepatitis, Vol. 18, No. 1, 2011,
pp. 1-7. doi:10.1111/j.1365-2893.2010.01366.x
[21] A. K. Singal and B. S. Anand, “Management of Hepatitis
C Virus Infection in HIV/HCV Co-Infected Patients:
Clinical Review,” World Journal of Gastroenterology,
Vol. 15, No. 30, 2009, pp. 3713-3824.
doi:10.3748/wjg.15.3713
[22] A. Pohl, et al., “Serum Aminotransferase Levels and
Platelet Counts as Predictors of Degree of Fibrosis in
Chronic Hepatitis C Virus Infection,” The American
Journal of Gastroenterology, Vol. 96, No. 11, 2001, pp.
3142-3146. doi:10.1111/j.1572-0241.2001.05268.x
[23] R. Testa, et al., “Noninvasive Ratio Indexes to Evaluate
Fibrosis Staging in Chronic Hepatitis C: Role of Platelet
Count/Spleen Diameter Ratio Index,” Journal of Internal
Medicine, Vol. 260, No. 2, 2006, pp. 142-150.
doi:10.1111/j.1365-2796.2006.01673.x
[24] M. Osada, et al., “Causes of Thrombocytopenia in
Chronic Hepatitis C Viral Infection,” Clinical and Appl
ied Thrombosis Hemostasis, Vol. 18, No. 3, 2012, pp.
272-280. doi:10.1177/1076029611429124
[25] A. A. M. Shaheen and R. P. Myers, “Diagnostic Accuracy
of the Aspartate Aminotransferase-to-Platelet Ratio Index
for the Prediction of Hepatitis C-Related Fibrosis: A Sys-
tematic Review,” Hepatology, Vol. 46, No. 3, 2007, pp.
912-921. doi:10.1002/hep.21835
[26] H.-H. Thein, et al., “Estimation of Stage-Specific Fibrosis
Progression Rates in Chronic Hepatitis C Virus Infection:
A Meta-Analysis and Meta-Regression,” Hepatology, Vol.
48, No. 2, 2008, pp. 418-431. doi:10.1002/hep.22375
[27] C. S. Graham, et al., “Influence of Human Immunode-
ficiency Virus Infection on the Course of Hepatitis C Virus
Infection: A Meta-Analysis,” Clinical Infectious Diseases,
Vol. 33, No. 4, 2001, pp. 562-569. doi:10.1086/321909
[28] P. J. Ballem, et al., “Kinetic Studies of the Mechanism of
Thrombocytopenia in Patients with Human Immunodefi-
ciency Virus Infection,” The New England Journal of
Medicine, Vol. 327, No. 25, 1992, pp. 1779-1784.
doi:10.1056/NEJM199212173272503
[29] The American Society of Hematology ITP Practice
Guideline Panel, “Diagnosis and Treatment of Idiopathic
Thrombocytopenic Purpura: Recommendations of the
American Society of Hematology,” Annals Internal Medi-
cine, Vol. 126, No. 4, 1997, pp. 319-326.
[30] M. W. Fried, “Side Effects of Therapy of Hepatitis C and
Their Management,” Hepatology, Vol. 36, No. 5B, 2002,
pp. S237-S244. doi:10.1053/jhep.2002.36810
[31] T. L. Kauf, et al., “Trends in the Prevalence of Thrombo-
cytopenia among Individuals Infected with Hepatitis C
Virus in the United States, 1999-2008,” BMC Research
Notes, Vol. 5, No. 1, 2012, p. 142.
doi:10.1186/1756-0500-5-142
[32] G. Cheng, et al., “Eltrombopag for Management of Chro-
nic Immune Thrombocytopenia (RAISE): A 6-Month,
Randomised, Phase 3 Study,” The Lancet, Vol. 377, No.
9763, 2011, pp. 393-402.
doi:10.1016/S0140-6736(10)60959-2
[33] C. Neunert, et al., “The American Society of Hematology
2011 Evidence-Based Practice Guideline for Immune
Thrombocytopenia,” Blood, Vol. 117, No. 16, 2011, pp.
4190-4207. doi:10.1182/blood-2010-08-302984